News

Press Release
RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype
Novel features of next-generation design promise to serve and expand the dermal injectable marketVANCOUVER, BC... ...
Press Release
RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial
German-based trial to test RCS-01 cell therapy treatment for aged and sun-damaged skin VANCOUVER, BC... ...
As Seen In
5 Questions with David Hall
Click here to view the article on Cantech LetterVancouver-based RepliCel Life Sciences (TSXV:RP) concentrated on... ...
Press Release
RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis
ReaCT Trial at University of British Columbia Treating Patients with Autologous CellTherapyVANCOUVER, BC – June... ...
Press Release
RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED... ...
Events
RepliCel Life Sciences Announces Participation in 23rd World Congress of Dermatology, Vancouver, BC
Conference program to include presentations on the clinical development of RepliCel’s skin rejuvenation, hair regeneration,... ...
Press Release
RepliCel Life Sciences Announces Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED... ...
As Seen In
Japan’s Gambit for Cell Therapy Clinical Trials
Please click here to visit Fisher BioServices Blog. Posted by Richard Tsai on May 28,... ...
Events
RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference
Clinical trial at the University of British Columbia now recruiting patients VANCOUVER, BC – May... ...
As Seen In
Stem cell ‘Wild West’ takes root amid lack of US regulation
Business | By Matthew Perrone | AP May 18, 2015 In this Dec. 5, 2014... ...
As Seen In
Injured Athletes Could get Back in the Game Putting New Cells to Work on old Injuries
Clinical trials underway for chronic Achilles tendinosis By: Tammey George Being sidelined due to an... ...
As Seen In
Impact Magazine: Aching Achilles?
Regenerative Medicine Promises New Cure for Chronic Tendon InjuriesBy Dr. Jack TauntonA Regerative Cell therapy... ...
As Seen In
The Province: UBC achilles research could be key to revolutionary treatment
University studying the injection of cultivated cells from one’s own body to speed the healing... ...
Press Release,Events
RepliCel Life Sciences Selected to Present at Cavendish Global Health Impact Forum
Unique forum brings together leading family offices and foundations seeking impactful investment and philanthropic opportunities... ...
As Seen In
Stockhouse: Tech Roundup – RepliCel (V.RP) grows, SoMedia (V.VID) profits, WiLAN (WILN) flounders
By: Gaalen Engen First here’s a little biotech. RepliCel Life Sciences (TSX: V.RP, Stock Forum)... ...
Press Release
RepliCel Announces 2014 Fourth Quarter and Year-End Financial Results
VANCOUVER, BC – April 29, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP),... ...
As Seen In
Japan’s Take on Regenerative Medicine: Early Commercialization, Early Reimbursement
By Gail Dutton, Contributing Editor Follow Me On Twitter @GailLdutton New regulations accelerating the approval... ...
As Seen In
How to Grow a Regenerative Medicine Industry in Canada: Michael May of CCRM
Source: George S. Mack of The Life Sciences Report (4/23/15)There’s a new kind of incubator... ...
As Seen In
Cell Therapy is “Hair Raising” in a Good Way
RepliCel Targets Low-Risk, Near-Term Opportunities in Regenerative MedicineBy: Gail DuttonThe regenerative medicine company RepliCel Life... ...
Press Release
RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis
The University of British Columbia Clinical Research Ethics Board Clears Clinical Trial to Proceed with... ...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.